Increasing TIMP3 expression by hypomethylating agents diminishes soluble MICA, MICB and ULBP2 shedding in acute myeloid leukemia, facilitating NK cell-mediated immune recognition

Acute myeloid leukemia (AML) is a disease with great morphological and genetic heterogeneity, which complicates its prognosis and treatment. The hypomethylating agents azacitidine (Vidaza(®), AZA) and decitabine (Dacogen(®), DAC) have been approved for the treatment of AML patients, but their mechan...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Oncotarget
Autors principals: Raneros, Aroa Baragaño, Puras, Alfredo Minguela, Rodriguez, Ramon M., Colado, Enrique, Bernal, Teresa, Anguita, Eduardo, Mogorron, Adela Vasco, Gil, Alberto Chaparro, Vidal-Castiñeira, Jose Ramon, Márquez-Kisinousky, Leonardo, Bulnes, Paula Díaz, Marin, Amelia Martinez, Garay, García Maria Carmen, Suarez-Alvarez, Beatriz, Lopez-Larrea, Carlos
Format: Artigo
Idioma:Inglês
Publicat: Impact Journals LLC 2017
Matèries:
Research Paper
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC5458262/
https://ncbi.nlm.nih.gov/pubmed/28404876
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.18632/oncotarget.16657
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars